标题：
索凡替尼在中美患者中的药代动力学特征及安全性比较
报告人：
Arvind Dasari
作者：
A Dasari1, S Paulson2, E Hamilton3, J Wang4, M Sung5, G Falchook6, C Tucci7, K Li7, C Chien7, J Kauh7, M Kani
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia V Sequist;
Press release released: September 29, 2019 (Sun)
>> See press release here
Presentation webcast & call: September 30, 2019 (Mon)
2pm CEST (1pm BST/8am EDT/8pm HKT)
>> Click here for the webcast replay
MA14.05 - A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)
Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain
Session:MA14 - The Adequate MTarget
地址： Westin St. Francis Hotel, San Francisco, CA
日期： 2019年1月9日（星期三）
时间： 9:30am PST (12:30pm EST/5:30pm BST)
录音： 请下载附带的演示文稿
[audio mp3="http://www.chi-med.com/wp-co
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
The FRESCO Randomized Clinical Trial
Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO
Presenter:
Yu-Xian Bai
Other Authors:
Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F
4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor
Presenter/Authors
M. M. Frigault1, S. Signoretti2, A. Markovets
Pharmacokinetics of Fruquintinib in Humans
Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA
Abstract #: PII-116
Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa
Announcement released: 7am BST (3pm HKT/3am EDT)
» See announcement here
Presentation webcast & call: 9am BST (5pm HKT/5am EDT)
» Click here for a video of the webcast
US conference call: 9am EDT (1pm BST/9pm HKT)
Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su
Abstract
Purpose
Patients with advanced non‒small-cell lung
Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand
Abstract #: ABS093
Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma
S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1
1 Barts Health NHS Trust, Barts Can
OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han
OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T
JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116)
Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su
Venue: IA
Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET
Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong
Venue: Chinese Society of Clinical Oncology Annual Meeting
Session: Esophageal Cancer
Presenter: Jif
In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer
Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen
The Royal Society of Medicine, London, UK
Please visit rsm.ac.uk for more information.
A video recording of the 20-minute presentation is available.
RSM video link
Note: there is a 25-second audio error at 2:55.
Announcement released: 7am BST (2am EDT, 2pm HKT)
» See announcement here
Presentation webcast & call: 9am BST (4pm HKT)
» click here for a video of the webcast
US conference call: 9am EDT (2pm BST)
» To parti
Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal
Abstract
Pur
A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO)
Venue: American Society of Clinical Oncol
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC)
Venue: American Society of Clinical Oncology Annual Meeti
Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models
Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,
Introduction
The Future of Targeted Cancer Therapy In Lung Cancer
Post-POC Portfolio
Pre-POC Portfolio
Research Strategy
Transforming into a Fully Integrated Global Biopharma
Wed. Mar 29, 9:30am - South Place Hotel, London, UK
» Cli
Announcement released: 7am GMT
» See announcement here
Webcast presentation & conf call: 9am GMT (5pm HKT)
» click here for a video of the webcast (available for six months)
» To participate by phone, please us
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)
Authors: J.M. Xu, J. Li, C.M. Bai, N. Xu, Z.W. Zhou, Z.P. Li, C.C. Zhou, W. Wang, J. Li, C. Qi, Y. Hua, W.G. Su
Summary: The current Phase